Engineering T cell-selective chemokine inhibitors through network-level directed evolution
Abstract
Immune-mediated inflammatory diseases (IMIDs) are sustained by chemokine-driven recruitment of effector T cells. Although direct suppression of T cell function can be effective, systemic immunosuppression and infection risk limit clinical utility. Targeting chemokine networks offers an alternative strategy, yet chemokine redundancy has hindered the development of clinically effective inhibitors. Tick evasins overcome chemokine redundancy by binding multiple chemokines. Here we show that network-level directed evolution of class B evasin-derived peptides generates T cell-selective chemokine inhibitors. In contrast to analogous class A-derived peptides, these preferentially bind and inhibit chemokines that drive T cell migration. Structural modelling of chemokine:peptide complexes and structure-guided mutagenesis suggest that evasin-derived peptides sterically occlude receptor-binding surfaces and that class B-derived peptides exhibit a more compact organisation of key interaction hotspots than a previously characterised class A-derived peptide. Together, these findings suggest that anti-chemokine peptide specificity can be engineered through scaffold choice and network-level directed evolution.
Related
- Targeting the CDK4-Cyclin D Complex: A New Generation of Selective Kinase Inhibitors for Cancer Therapy
- The safety of selective COX-2 inhibitors in tonsillectomy patients: a systematic review
- Comparative in Silico Toxicological Assessment of 16 Selective COX-2 Inhibitors (Coxibs) Using Multi-Platform Predictive Models
- Cellular uptake of folate-olaparib conjugates via folate receptor-mediated endocytosis: Potential for selective delivery of DNA damage response inhibitors into tumour cells
- Self-Organized Explainable Symbolic EEG Feature Engineering Using Directed Lobish and Previous-Next Pattern: A Proof-of-Concept Study on Dementia Classification
BibTeX
@article{payne2026engineering,
title = {{Engineering T cell-selective chemokine inhibitors through network-level directed evolution}},
author = {Megan Payne and Fernando Durães and Charlie J. Clark and Emma Wilde and Kalimuthu Karuppanan and Soumyanetra Chandra and Paul E. Brennan and David J. Hodson and Gintare Smagurauskaite and Shoumo Bhattacharya},
journal = {Communications Biology},
year = {2026},
month = oct,
doi = {10.1038/s42003-026-11117-8},
url = {https://www.nature.com/articles/s42003-026-11117-8},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Engineering T cell-selective chemokine inhibitors through network-level directed evolution
AU - Megan Payne
AU - Fernando Durães
AU - Charlie J. Clark
AU - Emma Wilde
AU - Kalimuthu Karuppanan
AU - Soumyanetra Chandra
AU - Paul E. Brennan
AU - David J. Hodson
AU - Gintare Smagurauskaite
AU - Shoumo Bhattacharya
PY - 2026
DA - 2026/10/14
JO - Communications Biology
DO - 10.1038/s42003-026-11117-8
UR - https://www.nature.com/articles/s42003-026-11117-8
AB - Immune-mediated inflammatory diseases (IMIDs) are sustained by chemokine-driven recruitment of effector T cells. Although direct suppression of T cell function can be effective, systemic immunosuppression and infection risk limit clinical utility. Targeting chemokine networks offers an alternative strategy, yet chemokine redundancy has hindered the development of clinically effective inhibitors. Tick evasins overcome chemokine redundancy by binding multiple chemokines. Here we show that network-level directed evolution of class B evasin-derived peptides generates T cell-selective chemokine inhibitors. In contrast to analogous class A-derived peptides, these preferentially bind and inhibit chemokines that drive T cell migration. Structural modelling of chemokine:peptide complexes and structure-guided mutagenesis suggest that evasin-derived peptides sterically occlude receptor-binding surfaces and that class B-derived peptides exhibit a more compact organisation of key interaction hotspots than a previously characterised class A-derived peptide. Together, these findings suggest that anti-chemokine peptide specificity can be engineered through scaffold choice and network-level directed evolution.
SN - 2399-3642
ER -